Kancera announces start of clinical Phase Ib study of KAND567
2019-06-04
The clinical Phase Ib study of intravenous administered KAND567 has started and is planned to be completed during the third quarter of 2019. KAND567 has previously been shown to be well tolerated and to have good pharmacokinetic properties when administered orally to 62 healthy subjects.
Kancera develops drugs that counteract damage during acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively reduce the inflammation of the heart and vessels after myocardial infarction.
In the clinical Phase Ib study, KAND567 is administered intravenously to 27 healthy subjects. The aim of the study is to evaluate safety, tolerance and exposure. The results will form the basis for the intravenous administration of KAND567 in the upcoming Phase IIa clinical trial in patients with myocardial infarction.
The study is carried out in collaboration with SCRO and CTC in Uppsala, Sweden. SCRO and CTC are established contract research organizations that carry out clinical studies according to the quality standard GCP (Good Clinical Practice).
About Kancera AB (publ)
Kancera develops drugs that counteract damage during acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively and selectively reduce the inflammation of the heart and vessels following a heart attack and is expected to enter the clinical phase II study in 2019. Since scientific studies have shown elevated levels of fractalkine not only in heart attacks but also in inflammatory diseases and certain forms of cancer, there are several possible development opportunities for the fractalkine blockers KAND567 and KAND145. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell’s ability to be repaired. Kancera operates at Karolinska Institutet Science Park in Stockholm. The share is traded on Nasdaq First North. FNCA Sweden AB (tel. 08-528 00 399, info@fnca.se) is the company’s Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB.
For further information, contact:
Thomas Olin, CEO: +46-(0)735-20 40 01
Adress:
Kancera AB (publ)
Karolinska Institutet Science Park
Banvaktsvägen 22
SE 171 48 Solna
Welcome to visit our home-page: www.kancera.com
Back